SRR8613737
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.450
- PROTEIN_SECRETION+0.380
- XENOBIOTIC_METABOLISM+0.310
- UV_RESPONSE_DN+0.290
- HEDGEHOG_SIGNALING+0.260
- PANCREAS_BETA_CELLS+0.260
- BILE_ACID_METABOLISM+0.240
- FATTY_ACID_METABOLISM+0.230
- COAGULATION+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V2-0.590
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V1-0.450
- INTERFERON_ALPHA_RESPONSE-0.420
- MITOTIC_SPINDLE-0.390
- WNT_BETA_CATENIN_SIGNALING-0.380
- DNA_REPAIR-0.360
- INTERFERON_GAMMA_RESPONSE-0.290
- NOTCH_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518290 | — | F | 0.854 |
| 2 | SRR8518177 | — | F | 0.845 |
| 3 | GSM6454747 | — | F | 0.806 |
| 4 | SRR35579825 | — | B | 0.805 |
| 5 | 60703_S134 | — | cohortA1 | 0.805 |
| 6 | TCGA-97-7547-01A-11R-2039-07 | — | cohortA1 | 0.801 |
| 7 | SRR8518184 | — | F | 0.792 |
| 8 | TCGA-73-4677-01A-01R-1206-07 | — | cohortA2 | 0.786 |
| 9 | SRR8613744 | — | F | 0.786 |
| 10 | SRR8518146 | — | F | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |